Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.63 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.73 |
| ▸ | USP2 | O75604 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | HAT1 | O14929 | 4/20 | 0.73 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.73 |
| ▸ | HTT | P42858 | 4/20 | 0.73 |
| ▸ | RECQL | P46063 | 3/20 | 0.73 |
| ▸ | CASP7 | P55210 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | CASP1 | P29466 | 2/20 | 0.73 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | TST | Q16762 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | HBB | P68871 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244132 | 0.99 | MEN1 (0.72) | MEN1KMT2AUSP2KDM4EHAT1 | |
| SCHEMBL10324834 | 0.95 | MEN1 (0.70) | MEN1KMT2AUSP2KDM4EHAT1 | |
| SCHEMBL50097 | 0.92 | MEN1 (0.74) | MEN1KMT2AUSP2KDM4EHAT1 | |
| SCHEMBL6369069 | 0.91 | MEN1 (0.73) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Water SCHEMBL2005233 | 0.90 | MEN1 (0.72) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL296802 | 0.89 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL21805317 | 0.89 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL618997 | 0.89 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL535031 | 0.88 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL50154 | 0.88 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975102-B2 | All-in-one lyophilized multivitamin emulsion for parenteral application | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2024-05-07 | — | — | US | claimed |
| WO-2021261599-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR NOVEL CORONA VIRUS INFECTIOUS DISEASE | 荒木 誠一 | 2021-12-30 | — | — | WO | claimed |
| CN-112932991-A | Phospholipid composition, preparation method thereof and scalp care solution containing same | 广州增城潮徽生物技术有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-112638357-A | Composition for promoting differentiation or proliferation of human adipose-derived stem cells | 株式会社LG生活健康 | 2021-04-09 | — | — | CN | claimed |
| US-20210032725-A1 | Methods of Rare Earth Metal Recovery from Electronic Waste | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2021-02-04 | — | — | US | claimed |
| US-20200297638-A1 | All-in-one lyophilized multivitamin emulsion for parenteral application | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2020-09-24 | — | — | US | claimed |
| CN-106674225-B | A kind of Riboflavin sodium phosphate compound and its pharmaceutical composition | 珠海同源药业有限公司 | 2019-04-02 | — | — | CN | claimed |
| CN-106674225-A | Riboflavin sodium phosphate compound and pharmaceutical composition thereof | 珠海同源药业有限公司 | 2017-05-17 | — | — | CN | claimed |
| CN-104327120-B | A kind of Riboflavin sodium phosphate compound injection and preparation method thereof | 江西国药有限责任公司 | 2016-08-17 | — | — | CN | claimed |
| CN-105399772-A | Synthetic method and technology of riboflavin sodium phosphate | TIANJIN FENGRUN CHEMICAL TRADE CO LTD | 2016-03-16 | — | — | CN | claimed |
| CN-102617643-A | Riboflavin sodium phosphate compound | JINXIU HUANG | 2012-08-01 | — | — | CN | claimed |
| CN-102260291-A | Riboflavin sodium phosphate crystalline compound, pharmaceutical composition thereof, and preparation method thereof | — | 2011-11-30 | — | — | CN | claimed |
| US-20110117194-A1 | PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER | HANALL BIOPHARMA CO., LTD. (KR) | 2011-05-19 | — | — | US | claimed |
| EP-2281557-A2 | PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER | HanAll Biopharma Co., Ltd. (KR) | 2011-02-09 | — | — | EP | claimed |
| EP-2066321-A2 | TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS | Lutonix, Inc. (US) | 2009-06-10 | — | — | EP | claimed |
| US-20080175887-A1 | drug delivering by oral, nasal or pulmonary administration, of rapamycin or paclitaxel drug; additive enhances absorption of drug into body tissue; PEG-fatty acids esters, PEG-fatty alcohol ethers, polyethylene glycol sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers | LUTONIX, INC. | 2008-07-24 | — | — | US | claimed |
| WO-2008063581-A2 | TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS | LUTONIX, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20030091648-A1 | Process for producing coated preparation and its use | KAKIGUCHI YOSHITOMI (JP) | 2003-05-15 | — | — | US | claimed |
| EP-0497177-B1 | Vitamin containing formulations and their production | HOFFMANN LA ROCHE (CH) | 1995-01-18 | — | — | EP | claimed |
| US-5185336-A | Spray drying aqueous solution or suspension | HOFFMANN-LA ROCHE INC. (US) | 1993-02-09 | — | — | US | claimed |